title: Hyperoxic acute lung injury.
abstract: Prolonged breathing of very high F(IO(2)) (F(IO(2)) ≥ 0.9) uniformly causes severe hyperoxic acute lung injury (HALI) and, without a reduction of F(IO(2)), is usually fatal. The severity of HALI is directly proportional to P(O(2)) (particularly above 450 mm Hg, or an F(IO(2)) of 0.6) and exposure duration. Hyperoxia produces extraordinary amounts of reactive O(2) species that overwhelms natural anti-oxidant defenses and destroys cellular structures through several pathways. Genetic predisposition has been shown to play an important role in HALI among animals, and some genetics-based epidemiologic research suggests that this may be true for humans as well. Clinically, the risk of HALI likely occurs when F(IO(2)) exceeds 0.7, and may become problematic when F(IO(2)) exceeds 0.8 for an extended period of time. Both high-stretch mechanical ventilation and hyperoxia potentiate lung injury and may promote pulmonary infection. During the 1960s, confusion regarding the incidence and relevance of HALI largely reflected such issues as the primitive control of F(IO(2)), the absence of PEEP, and the fact that at the time both ALI and ventilator-induced lung injury were unknown. The advent of PEEP and precise control over F(IO(2)), as well as lung-protective ventilation, and other adjunctive therapies for severe hypoxemia, has greatly reduced the risk of HALI for the vast majority of patients requiring mechanical ventilation in the 21st century. However, a subset of patients with very severe ARDS requiring hyperoxic therapy is at substantial risk for developing HALI, therefore justifying the use of such adjunctive therapies.
authors.affiliation: Respiratory Care Services, Department of Anesthesia, University of California, San Francisco at San Francisco General Hospital, San Francisco, California 94110, USA. rich.kallet@ucsf.edu
authors.forename: Richard H
authors.initials: RH
authors.lastname: Kallet
authors.forename: Michael A
authors.initials: MA
authors.lastname: Matthay
mesh_terms: D055371:Acute Lung Injury / Q000209:etiology* / Q000503:physiopathology; D000818:Animals; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D018496:Hyperoxia / Q000209:etiology* / Q000503:physiopathology; D010100:Oxygen / Q000008:administration & dosage / Q000009:adverse effects; D010102:Oxygen Inhalation Therapy / Q000009:adverse effects*; D010313:Partial Pressure; D017382:Reactive Oxygen Species / Q000009:adverse effects / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism; D013997:Time Factors
chemical_list: D016207:Cytokines; D017382:Reactive Oxygen Species; D013482:Superoxide Dismutase; D010100:Oxygen